Core Viewpoint - Jingtai Holdings (02228) has seen its stock price increase by over 40% in January, with a current rise of 6.18% to HKD 13.75, and a trading volume of HKD 819 million [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company, ReviR Technology, received clinical trial approval from the National Medical Products Administration for its small molecule drug RTX-117, which is set to begin Phase I clinical trials in Q1 2026 [1] - RTX-117 is the first innovative drug in China targeting Charcot-Marie-Tooth disease (CMT) and is the first project to enter clinical trials from a series of rare disease drug pipelines developed in collaboration with AI and robotics [1] Group 2: Market Analysis - Guolian Minsheng Securities released a report stating that Jingtai Holdings has established a competitive edge in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and key market positioning [1] - The approval of RTX-117 for clinical trials marks the beginning of the value realization phase for its technology platform, with significant potential for performance elasticity and valuation restructuring as the pipeline continues to expand [1]
港股异动 | 晶泰控股(02228)再涨超6% RTX-117临床获批 晶泰控股AI平台价值进一步验证